21.92
price up icon3.79%   0.80
after-market 시간 외 거래: 21.92
loading
전일 마감가:
$21.12
열려 있는:
$21.04
하루 거래량:
1.01M
Relative Volume:
0.75
시가총액:
$1.98B
수익:
$23.38M
순이익/손실:
$-155.22M
주가수익비율:
-10.01
EPS:
-2.19
순현금흐름:
$-134.36M
1주 성능:
-0.41%
1개월 성능:
+3.30%
6개월 성능:
-12.88%
1년 성능:
-34.99%
1일 변동 폭
Value
$20.96
$22.27
1주일 범위
Value
$20.50
$22.86
52주 변동 폭
Value
$13.45
$44.42

Ideaya Biosciences Inc Stock (IDYA) Company Profile

Name
명칭
Ideaya Biosciences Inc
Name
전화
650-443-6209
Name
주소
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Name
직원
131
Name
트위터
Name
다음 수익 날짜
2024-11-05
Name
최신 SEC 제출 서류
Name
IDYA's Discussions on Twitter

IDYA을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
IDYA
Ideaya Biosciences Inc
21.92 1.98B 23.38M -155.22M -134.36M -2.19
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-11-18 개시 Stephens Overweight
2024-11-05 다운그레이드 Leerink Partners Outperform → Market Perform
2024-10-24 개시 UBS Buy
2024-10-15 개시 Cantor Fitzgerald Overweight
2024-07-08 개시 Mizuho Outperform
2024-03-08 개시 BTIG Research Buy
2023-08-08 개시 SVB Securities Outperform
2023-05-24 개시 Goldman Buy
2023-04-24 업그레이드 Stifel Hold → Buy
2023-03-23 개시 Berenberg Buy
2023-02-28 개시 RBC Capital Mkts Outperform
2022-12-28 개시 CapitalOne Overweight
2022-10-27 개시 Citigroup Buy
2022-08-15 다운그레이드 Stifel Buy → Hold
2022-07-18 재개 Oppenheimer Outperform
2022-03-10 업그레이드 Stifel Hold → Buy
2021-09-23 개시 Stifel Hold
2021-06-04 재개 Robert W. Baird Outperform
2021-03-11 개시 Guggenheim Buy
2020-10-07 개시 Wedbush Outperform
2020-09-01 개시 Northland Capital Outperform
2020-07-13 업그레이드 JP Morgan Neutral → Overweight
2020-06-17 재확인 H.C. Wainwright Buy
2020-04-06 개시 H.C. Wainwright Buy
2020-03-13 개시 ROTH Capital Buy
2019-10-17 개시 Oppenheimer Outperform
2019-09-10 개시 Robert W. Baird Outperform
2019-06-17 개시 Citigroup Buy
2019-06-17 개시 JP Morgan Neutral
2019-06-17 개시 Jefferies Buy
모두보기

Ideaya Biosciences Inc 주식(IDYA)의 최신 뉴스

pulisher
Jun 17, 2025

Rhumbline Advisers Increases Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World

Jun 17, 2025
pulisher
Jun 16, 2025

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Holdings Lifted by GAMMA Investing LLC - Defense World

Jun 16, 2025
pulisher
Jun 16, 2025

Handelsbanken Fonder AB Raises Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World

Jun 16, 2025
pulisher
Jun 16, 2025

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

Jun 16, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Comments on IDYA FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Transcript : IDEAYA Biosciences, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener

Jun 09, 2025
pulisher
Jun 08, 2025

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Purchased by California State Teachers Retirement System - Defense World

Jun 08, 2025
pulisher
Jun 02, 2025

IDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations Events - Longview News-Journal

Jun 02, 2025
pulisher
Jun 02, 2025

IDEAYA Biosciences CEO Set for Major Healthcare Conference Double-Header: Jefferies and Goldman Sachs - Stock Titan

Jun 02, 2025
pulisher
May 31, 2025

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress

May 31, 2025
pulisher
May 30, 2025

Ideaya Biosciences announces inducement grants under Nasdaq listing rule - TipRanks

May 30, 2025
pulisher
May 30, 2025

IDEAYA Biosciences (IDYA) Grants Stock Options to New Employees | IDYA Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Purchased by Nuveen Asset Management LLC - Defense World

May 30, 2025
pulisher
May 25, 2025

IDEAYA Biosciences (NASDAQ:IDYA) Price Target Raised to $66.00 - Defense World

May 25, 2025
pulisher
May 25, 2025

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $54.27 Consensus PT from Brokerages - Defense World

May 25, 2025
pulisher
May 23, 2025

(IDYA) Proactive Strategies - news.stocktradersdaily.com

May 23, 2025
pulisher
May 22, 2025

JP Morgan Raises Price Target for IDEAYA Biosciences (IDYA) | ID - GuruFocus

May 22, 2025
pulisher
May 22, 2025

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Acquired by Ameriprise Financial Inc. - Defense World

May 22, 2025
pulisher
May 21, 2025

BNP Paribas Financial Markets Buys 10,543 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World

May 21, 2025
pulisher
May 20, 2025

Jane Street Group LLC Reduces Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World

May 20, 2025
pulisher
May 20, 2025

Bank of America Corp DE Acquires 41,390 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World

May 20, 2025
pulisher
May 15, 2025

January 2026 Options Now Available For IDEAYA Biosciences - Nasdaq

May 15, 2025
pulisher
May 14, 2025

Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849 (NASDAQ:IDYA) - Seeking Alpha

May 14, 2025
pulisher
May 12, 2025

(IDYA) Investment Analysis - news.stocktradersdaily.com

May 12, 2025
pulisher
May 12, 2025

FY2025 EPS Estimates for IDYA Cut by Cantor Fitzgerald - Defense World

May 12, 2025
pulisher
May 12, 2025

Stifel Financial Corp Sells 3,834 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World

May 12, 2025
pulisher
May 11, 2025

Dimensional Fund Advisors LP Has $8.91 Million Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World

May 11, 2025
pulisher
May 10, 2025

16,769 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Acquired by Raymond James Financial Inc. - Defense World

May 10, 2025
pulisher
May 10, 2025

Brokers Issue Forecasts for IDYA Q2 Earnings - Defense World

May 10, 2025
pulisher
May 10, 2025

Leerink Partnrs Has Bullish Estimate for IDYA Q2 Earnings - Defense World

May 10, 2025
pulisher
May 09, 2025

IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer - Barchart.com

May 09, 2025
pulisher
May 07, 2025

Ideaya Biosciences (IDYA) Faces Market Reaction Following FDA Le - GuruFocus

May 07, 2025
pulisher
May 07, 2025

IDEAYA Biosciences Reports Q1 2025 Financial Results - TipRanks

May 07, 2025
pulisher
May 07, 2025

IDEAYA Biosciences (NASDAQ:IDYA) Shares Down 10.2% After Earnings Miss - Defense World

May 07, 2025
pulisher
May 06, 2025

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Bought by Mariner LLC - Defense World

May 06, 2025
pulisher
May 06, 2025

IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - The Malaysian Reserve

May 06, 2025
pulisher
May 06, 2025

IDEAYA Gets FDA Clearance to Initiate Clinical Trial of Antibody Drug Conjugate Program in Solid Tumors - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

IDEAYA Biosciences Posts Q1 Net Loss; Cash Runway Extended Through 2029 - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

IDEAYA gets approval to begin trial for its antibody drug conjugate in solid tumors - Seeking Alpha

May 06, 2025
pulisher
May 06, 2025

IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Ideaya Biosciences (IDYA) Achieves Major Milestones in Oncology Programs | IDYA Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Ideaya Biosciences (IDYA) Advances with FDA Approval for IDE849 Trial | IDYA Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

IDEAYA Biosciences Announces US FDA IND-Clearance For IDE849, A Potential First-In-Class DLL3 TOP1 ADC, For A Phase 1 Study In Solid Tumors - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

FDA clears IDEAYA’s Phase 1 trial for new cancer drug By Investing.com - Investing.com South Africa

May 06, 2025
pulisher
May 06, 2025

FDA clears IDEAYA’s Phase 1 trial for new cancer drug - Investing.com

May 06, 2025
pulisher
May 06, 2025

IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors – Company Announcement - Financial Times

May 06, 2025
pulisher
May 05, 2025

IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 Mutations - Barchart.com

May 05, 2025
pulisher
May 05, 2025

IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanoma - Barchart.com

May 05, 2025
pulisher
May 05, 2025

Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Insider Monkey

May 05, 2025
pulisher
May 04, 2025

IDEAYA Biosciences (IDYA) to Release Quarterly Earnings on Tuesday - Defense World

May 04, 2025

Ideaya Biosciences Inc (IDYA) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
자본화:     |  볼륨(24시간):